Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + vitamin d
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of entecavir, a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor, and vitamin D (colecalciferol). Entecavir is used for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication. Vitamin D stimulates intestinal absorption of calcium and phosphorus.
- Other names
- entecavir + colecalciferol
02
Targets
VDR (Vitamin D receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + vitamin d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + vitamin d.